Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia

The prognostic value of lymphocyte doubling time (LDT), expressed in months and obtained by means of a linear regression, has been studied in 99 previously untreated chronic lymphocytic leukemia (CLL) patients. LDT is defined as the period of time needed for lymphocytes to double in number the amount found at diagnosis. When the analysis was extended to the whole population, it showed clear differences in the life expectancy of patients with LDT of less than or equal to 12 months (median survival, 36 months; relative death rate [O/E] 1.57) compared with those with LDT of more than 12 months (median survival not yet reached; O/E, 0.37) (P < 0.001). The significance of LDT remained even after adjustments were made for age, sex, lymphocyte count, anemia, and thrombocytopenia. The lack of statistical significance after adjustment for Binet's clinical stage corresponds to the fact that clinical stages are not distributed homogeneously, high LDT being more frequently associated with earlier stages and low LDT with more advanced forms of the disease (P < 0.001). In this study LDT was a useful parameter in predicting disease progression. Patients in Stages A and B and with rapidly increasing lymphocytes counts became worse more frequently (33.3% and 29.1%, respectively, at 12 months after diagnosis) than those with a slow increase (no change in clinical stage at 12 months). It is concluded that since LDT appears to predict the progression of the disease, it is useful in the clinical management of CLL.

[1]  Ciril Rozman,et al.  Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance , 1986, British journal of haematology.

[2]  M. Antica,et al.  The relationship between membrane characteristics, functional reactivity of T‐lymphocytes, and the progression rate of B‐cell chronic lymphocytic leukemia , 1985, Cancer.

[3]  L. Zech,et al.  Prognostic information from cytogenetic analysis in chronic B- lymphocytic leukemia and leukemic immunocytoma , 1985 .

[4]  S. Molica,et al.  Prognosis of Chronic Lymphocytic Leukemia: Analysis of One Hundred Cases , 1984, Tumori.

[5]  E. Henderson,et al.  Benign monoclonal B cell lymphocytosis--a benign variant of CLL: clinical, immunologic, phenotypic, and cytogenetic studies in 20 patients. , 1984, Blood.

[6]  H. Theml,et al.  Management of CLL and allied disorders with reference to their immunology and proliferation kinetics. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[7]  M. Gobbi,et al.  Staging of chronic lymphocytic leukemia. , 1982, Blood.

[8]  E. Montserrat,et al.  Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases , 1982 .

[9]  B. Jakšić,et al.  Total Tumour Mass Score (TTM): a New Parameter in Chronic Lymphocytic Leukaemia , 1981, British journal of haematology.

[10]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[11]  E. Cronkite,et al.  Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia. , 1979, Blood.

[12]  J. Binet,et al.  A clinical staging system for chronic lymphocytic leukemia. Prognostic significance , 1977, Cancer.

[13]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[14]  E. Cronkite,et al.  Clinical staging of chronic lymphocytic leukemia. , 1975, Blood.

[15]  J. Gerrard,et al.  Letter: Sex-linked mental retardation. , 1974, Lancet.

[16]  W. Reeves,et al.  Survival in chronic lymphocytic leukemia. , 1973, Blood.

[17]  W. Dameshek Special Article: Chronic Lymphocytic Leukemia—an Accumulative Disease of Immunologically Incompetent Lymphocytes , 1967 .

[18]  D. Galton,et al.  The pathogenesis of chronic lymphocytic leukemia. , 1966, Canadian Medical Association journal.

[19]  G. Cartwright,et al.  Factors influencing the duration of survival of patients with chronic lymphocytic leukemia. , 1966, The American journal of medicine.